PRECISION BIOSCIENCES INC (DTIL) Form 8-K — Aug 6, 2026
Precision BioSciences reported a significant scientific milestone with the first clinical biopsy evidence of direct cccDNA elimination from its PBGENE-HBV program, a potential curative mechanism for chronic hepatitis B. The company also announced that PBGENE-HBV led to a 1-log reduction in cccDNA with less than 1% remaining in treated patients, demonstrating the durability of the treatment's effect. Financially, the company reported a net loss of $32.7 million for the quarter ended June 30, 2026, but maintained a strong cash position of $112.4 million, which it expects to fund operations through 2028.
Key figures
- Eps
- (1.26)
- Revenue
- 0
- Net Income
- (32.7) million
- Revenue Yoy
- less than $0.1 million
- Total Assets
- 125.9 million
- Cash Position
- 112.4 million
- Total Liabilities
- 80.6 million
- Shares Outstanding
- 26.4 million
- Total Stockholders Equity
- 45.3 million
- Research And Development Expenses
- 12.4 million
- General And Administrative Expenses
- 6.8 million
- Pg RNALoss
- 100% of evaluable patients
- Cash Runway
- through 2028
- Ccc DNAReduction
- 1-log (10-fold) reduction
- Ccc DNARemaining
- less than 1%
- Dilution Percent
- 0
Price after filing
Close on the filing date to close N calendar days later (from $7.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.